GlassScriptPhysician profile
Monisha Medhi
NPI 1104016096
$3,982.51
in general payments reported to CMS, 2019-2025
36 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $606 · 2021: $770 · 2022: $890 · 2023: $618 · 2024: $235 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $519.63 | 2019-2023 | Mounjaro, Humulin, Baqsimi |
| Tandem Diabetes Care, INC. | $394.27 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $317.33 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $278.67 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Becton, Dickinson and Company | $226.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $222.43 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $207.15 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.05 | 2019-2023 | Synjardy |
| Amneal Pharmaceuticals LLC | $148.69 | 2019-2022 | |
| Horizon Therapeutics Plc | $136.38 | 2022-2023 | Tepezza |
| Esperion Therapeutics, INC. | $130.65 | 2021 | |
| Abbvie INC. | $128.67 | 2019-2023 | |
| Radius Health, INC. | $105.81 | 2019-2022 | |
| Abbott Laboratories | $101.50 | 2019-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $93.72 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $91.61 | 2020-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $88.97 | 2021-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $78.38 | 2019-2020 | |
| Dexcom, INC. | $75.11 | 2019-2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $56.83 | 2019-2020 | |
| Corcept Therapeutics | $52.96 | 2019-2022 | |
| Pfizer INC. | $43.75 | 2019-2023 | |
| Embecta Corp. | $42.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascendis Pharma Endocrinology INC | $31.47 | 2023 | |
| Medtronic, INC. | $31.14 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Shire North American Group INC | $21.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.88 | 2023 | |
| Mannkind Corporation | $19.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.52 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.94 | 2019 | |
| Ibsa Pharma INC. | $14.59 | 2019 | |
| Beta Bionics, INC. | $14.35 | 2023 | Ilet Bionic Pancreas |
| Alfasigma USA, INC. | $14.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.07 | 2019 | |
| Lifescan, INC. | $12.92 | 2020 | |
| Merck Sharp & Dohme LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monisha Medhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.